National and Kapodistrian University of Athens
Υποομάδες νόσου στο πολλαπλό μυέλωμα: βιολογικές, κλινικές και θεραπευτικές προεκτάσεις
Abstract
dc:descriptionPlasma-cell dyscrasias concern diseases that are characterized by a malignant plasma-cell infiltration of bone marrow or/and other tissues as well as by the presence of paraprotein in serum. The term multiple myeloma includes a wide range of diseases with distinct clinical characteristics, biological parameters, and response to treatment.This realization raises a further clinical question: whether we could distinguish disease subgroups with similar characteristics that could predict patients’ response as well as the appropriate treatment. This question is the basis of the present doctoral thesis.We retrospectively studied 587 MGUS and MΜ patients (symptomatic and asymptomatic) since their diagnosis, during a period of 20 years. Beyond clinical data at diagnosis, we collected data on their course and response to treatment. The cytokines Syndecan-1 and TGF-b were measured, in order to clear their role. We studied separately MGUS & SMM patients that evolved to symptomatic disease. In MGUS patients no parameter with a specific prognostic value emerged, that could distinguish the patients that are going to evolve to MM. We however observed slightly higher evolution percentages in patients with IgG subtype, which presented higher immunoparesis percentages and higher median Syndecan-1 &ι TGF-b values, findings that were not statistically significant.Significant prognostic factors for SMM evolution were found to be: bone marrow infiltration >60% (p<0.001), FLCR >100 (p<0.001), monoclonal free light chain> 30 mg/L (p=0.002), non- IgG isotype (p= 0.013), pathologic free light chain ration (FLCR, p=0.035) & Syndecan-1 > 120pg/ml (p=0.001). In multiparameter analysis, only FLCR >100, abnormal FLCR, non- IgG isotype & Syndecan-1 levels kept their prognostic value.In symptomatic MM patients, prognostic parameters that were found to be important for prognosis were b2 microglobulin (ρ=0.000), LDH (ρ=0.009), bone marrow infiltration percentage (ρ=0.014) and FLCR (p=0.000). In addition, FLCR≥100 distinguished a subgroup of worse prognosis among IgG myeloma patients (OS 32 months VS 71 months).A distinct subgroup were patients that presented aberrant changes in Ig production (A-IgC) during their disease course. We observed that patients with light chain escape (LCE), Monoclonal Ig escape (MCE) and de-differentation (DD) had statistically shorter survival after A-IgC in comparison to those that had presented with clonal domination (CD). Nevertheless, since A-IgC consists a late event in MM patients’ course, overall survival of A-IgC patients’ did not differ from that of the total cohort.An interesting finding was the fact that patients with MM and bone plasmacytoma (BP) had a worse prognosis in comparison to the total cohort, with became worse when BP presented in spine, and thus we believe that the presence of BP in MM diagnosis consists an adverse prognostic factor, especially when the latter is located in spine.Furthermore, we estimated frailty score in MM patients, in order to evaluate its influence on MM patients’ survival. We realised that younger patients (<60 years) are generally in better physical condition, even when frail, and can overcome the undesirable effect of frailty. Another remarkable finding of our study is that the classic predictive survival markers in symptomatic patients with MM do not have the same value in fragile patients and in different age groups.Finally, we studied patients with an excellent response to IMIDs / dexamethasone on any treatment line. Patients with excellent response were present up to the 8th treatment line, which means that there is a subgroup of patients with MM who maintain a mild behavior for a long time. Complete responses were not mandatory for prolonged recessions, although it should be noted that the 4 patients that remain in long-term remission without evidence of disease had achieved sCR, having received IMID / dexamethasone on the 2nd treatment line.In our study we have distinguished some subgroups of patients with distinctive characteristics. However, it has been noticed that much remains to be done in the search for prognostic systems that predict response to treatment, disease progression and possible relapse.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Nikolaou, Eftychia
- Νικολάου, Ευτυχία
Subjects
dc:subject × 14Rights
dc:rights- Statement dc:rights
-
- BY_NC_SA
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44301